2.80

3.78% -0.11

After Hours: 2.81 0.01 +0.36%

Allogene Therapeutics Inc (ALLO)

Overview News Price History Option Chain Financials Discussions Forecast

Allogene Therapeutics Inc stock is traded at $2.80, with a volume of 1.18M. It is down -3.78% in the last 24 hours and up +6.46% over the past month. Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.

Previous Close:

$2.91

Open:

$2.85

24h Volume:

1.18M

Relative Volume:

0.55

Market Cap:

$576.10M

Revenue:

$95,000

Net Income/Loss:

$-327.27M

P/E Ratio:

-1.1429

EPS:

-2.45

Net Cash Flow:

$-239.25M

1W Performance:

+4.87%

1M Performance:

+6.46%

6M Performance:

-37.36%

1Y Performance:

-11.67%

1-Day Range:

$2.744

$3.01

1-Week Range:

$2.57

$3.01

52-Week Range:

$2.01

$5.775

Allogene Therapeutics Inc Stock (ALLO) Company Profile

Name

Allogene Therapeutics Inc

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

(650) 457-2700

Address

210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO

Employee

361

Twitter

@AllogeneTx

Next Earnings Date

2024-08-07

Latest SEC Filings

ALLO's Discussions on Twitter

Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-05-24	Downgrade	Guggenheim	Buy → Neutral
Jan-05-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Dec-08-23	Initiated	Citigroup	Buy
Jun-26-23	Resumed	Oppenheimer	Outperform
Mar-21-23	Initiated	Bernstein	Mkt Perform
Jan-24-23	Upgrade	JP Morgan	Neutral → Overweight
Jan-06-23	Upgrade	Robert W. Baird	Neutral → Outperform
Dec-12-22	Downgrade	BofA Securities	Buy → Underperform
Aug-10-22	Downgrade	Raymond James	Outperform → Mkt Perform
Jul-15-22	Upgrade	Goldman	Neutral → Buy
Jun-03-22	Initiated	Robert W. Baird	Neutral
Feb-28-22	Reiterated	B. Riley Securities	Buy
Oct-20-21	Initiated	Cowen	Outperform
Oct-08-21	Downgrade	Goldman	Buy → Neutral
Oct-08-21	Downgrade	Stifel	Buy → Hold
Sep-23-21	Upgrade	Raymond James	Mkt Perform → Outperform
Jun-21-21	Resumed	Jefferies	Buy
May-20-21	Upgrade	Truist	Hold → Buy
May-14-21	Initiated	B. Riley Securities	Buy
Jan-26-21	Upgrade	Stifel	Hold → Buy
Dec-10-20	Resumed	H.C. Wainwright	Buy
Nov-24-20	Initiated	BofA Securities	Buy
Oct-23-20	Initiated	RBC Capital Mkts	Outperform
Jun-01-20	Downgrade	Raymond James	Outperform → Mkt Perform
May-29-20	Reiterated	H.C. Wainwright	Buy
May-19-20	Upgrade	ROTH Capital	Neutral → Buy
May-15-20	Upgrade	Guggenheim	Neutral → Buy
May-14-20	Reiterated	H.C. Wainwright	Buy
May-14-20	Downgrade	SunTrust	Buy → Hold
Apr-13-20	Initiated	SunTrust	Buy
Mar-13-20	Initiated	H.C. Wainwright	Buy
Mar-05-20	Initiated	Stifel	Hold
Feb-24-20	Initiated	Berenberg	Hold
Dec-18-19	Initiated	JMP Securities	Mkt Outperform
Nov-04-19	Initiated	Canaccord Genuity	Buy
Aug-09-19	Initiated	BTIG Research	Buy
Jun-05-19	Initiated	ROTH Capital	Neutral
May-31-19	Initiated	Guggenheim	Neutral
May-23-19	Initiated	Stifel	Hold
Mar-29-19	Initiated	Piper Jaffray	Overweight

View All

Allogene Therapeutics Inc Stock (ALLO) Latest News

04:27 AM

Allogene Therapeutics (ALLO) Shares Dip 5.15% Amid Market Volati - GuruFocus.com

04:27 AM

08:30 AM

Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference - StockTitan

08:30 AM

07:31 AM

Perceptive Advisors LLC Takes Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat

07:31 AM

Sep 29, 2024

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Shares Purchased by Renaissance Technologies LLC - MarketBeat

Sep 29, 2024

Sep 27, 2024

Wall Street SWOT: Allogene stock navigates expanded rights and clinical milestones - Investing.com

Sep 27, 2024

Allogene Therapeutics (ALLO) Stock Jumps by 5.15% - GuruFocus.com

Sep 27, 2024

Wall Street SWOT: Allogene stock navigates expanded rights and clinical milestones By Investing.com - Investing.com South Africa

Sep 27, 2024

Lynx1 Capital Management LP Invests $5.19 Million in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat

Sep 27, 2024

Sep 26, 2024

Allogene reveals next-gen CAR T candidate for autoimmune disease - Investing.com

Sep 26, 2024

Allogene Therapeutics to Present Pre-Clinical Data - GlobeNewswire

Sep 26, 2024

Allogene Therapeutics to Present Pre-Clinical Data Highlighting the Potential of ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Diseases, at the American College of Rheumatology (ACR) Convergence - Yahoo Finance

Sep 26, 2024

Sep 24, 2024

ALLE stock rated an Underweight by Barclays - Knox Daily

Sep 24, 2024

Insider Selling: The Allstate Co. (NYSE:ALL) Insider Sells 36,367 Shares of Stock - Defense World

Sep 24, 2024

Market Momentum: Allarity Therapeutics Inc (ALLR) Registers a 1.36 Increase, Closing at 2.24 - The Dwinnex

Sep 24, 2024

Sep 23, 2024

ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit - The Bubble

Sep 23, 2024

ALLR INVESTOR ALERT: Edelson Lechtzin LLP Urges Allarity - GlobeNewswire

Sep 23, 2024

Seven Eight Capital LP Purchases 2,456 Shares of Allison Transmission Holdings, Inc. (NYSE:ALSN) - Defense World

Sep 23, 2024

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Expected to Post Q1 2026 Earnings of ($0.43) Per Share - MarketBeat

Sep 23, 2024

Sep 21, 2024

Sompo Asset Management Co. Ltd. Cuts Stock Position in The Allstate Co. (NYSE:ALL) - Defense World

Sep 21, 2024

Summit Trail Advisors LLC Grows Stock Holdings in The Allstate Co. (NYSE:ALL) - Defense World

Sep 21, 2024

Ensign Peak Advisors Inc Cuts Position in The Allstate Co. (NYSE:ALL) - Defense World

Sep 21, 2024

Sep 20, 2024

Aligos Therapeutics (NASDAQ:ALGS) Earns “Buy” Rating from HC Wainwright - Defense World

Sep 20, 2024

Primecap Management Co. CA Acquires 221,840 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat

Sep 20, 2024

Choreo LLC Makes New $237,000 Investment in Allison Transmission Holdings, Inc. (NYSE:ALSN) - Defense World

Sep 20, 2024

Sep 19, 2024

Primecap Management Co. CA Increases Stock Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - Defense World

Sep 19, 2024